NO20064123L - Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse - Google Patents

Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse

Info

Publication number
NO20064123L
NO20064123L NO20064123A NO20064123A NO20064123L NO 20064123 L NO20064123 L NO 20064123L NO 20064123 A NO20064123 A NO 20064123A NO 20064123 A NO20064123 A NO 20064123A NO 20064123 L NO20064123 L NO 20064123L
Authority
NO
Norway
Prior art keywords
erythromoefloquine
pharmaceutical blend
pharmaceutical
blend
iodophromefloquine
Prior art date
Application number
NO20064123A
Other languages
English (en)
Inventor
Robin Mark Bannister
Helen Frances Baker
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of NO20064123L publication Critical patent/NO20064123L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Et farmasøytisk preparat er i form av en enhetsdose omfattende 1 til 60 mg (+)-eiyfro-meflokin. Dette er ment for daglig dosering.
NO20064123A 2004-03-17 2006-09-13 Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse NO20064123L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406014.1A GB0406014D0 (en) 2004-03-17 2004-03-17 Pharmaceutical composition and use
PCT/GB2005/001014 WO2005089762A2 (en) 2004-03-17 2005-03-17 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition

Publications (1)

Publication Number Publication Date
NO20064123L true NO20064123L (no) 2006-09-13

Family

ID=32117884

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064123A NO20064123L (no) 2004-03-17 2006-09-13 Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse

Country Status (14)

Country Link
US (1) US20070202503A1 (no)
EP (1) EP1773340A2 (no)
JP (1) JP2007529488A (no)
KR (1) KR20070030182A (no)
CN (1) CN1929841A (no)
AU (1) AU2005224154A1 (no)
BR (1) BRPI0508855A (no)
CA (1) CA2558096A1 (no)
GB (1) GB0406014D0 (no)
IL (1) IL177751A0 (no)
MX (1) MXPA06010598A (no)
NO (1) NO20064123L (no)
WO (1) WO2005089762A2 (no)
ZA (1) ZA200607385B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108666A1 (en) * 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
CN114796216A (zh) * 2022-01-04 2022-07-29 南京医科大学 甲氟喹在防治全身代谢性炎症疾病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0966285T3 (da) * 1997-03-07 2002-10-28 Vernalis Res Ltd Anvendelse af (+)mefloquin til behandling af malaria
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0201025D0 (en) * 2002-01-17 2002-03-06 Arakis Ltd The treatment of degenerative diseases
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
GB0329236D0 (en) * 2003-12-17 2004-01-21 Arakis Ltd Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride

Also Published As

Publication number Publication date
AU2005224154A1 (en) 2005-09-29
BRPI0508855A (pt) 2007-08-28
CA2558096A1 (en) 2005-09-29
WO2005089762A2 (en) 2005-09-29
EP1773340A2 (en) 2007-04-18
WO2005089762A3 (en) 2005-11-03
ZA200607385B (en) 2008-05-28
IL177751A0 (en) 2006-12-31
GB0406014D0 (en) 2004-04-21
MXPA06010598A (es) 2007-01-23
US20070202503A1 (en) 2007-08-30
JP2007529488A (ja) 2007-10-25
CN1929841A (zh) 2007-03-14
KR20070030182A (ko) 2007-03-15

Similar Documents

Publication Publication Date Title
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
TW200716628A (en) Novel compounds
MX2009010977A (es) Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
AP2002002552A0 (en) Pharmaceutical compositions providing enhanced drug concentrations.
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
RS54187B1 (en) PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MX340538B (es) Compuestos amido y sus usos como farmaceuticos.
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
TW200517107A (en) Novel formulation
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application